23/09/2008 Page 1

Uploading C:\Program Files\Stnexp\Queries\10537538.str

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10814777.str

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2 STR

G1 O, N

Structure attributes must be viewed using STN Express query preparation.

=> s 12

SAMPLE SEARCH INITIATED 13:10:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0 PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L2

=> s 12 ful

FULL SEARCH INITIATED 13:10:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 35 TO ITERATE

23/09/2008 Page 2

100.0% PROCESSED 35 ITERATIONS 25 ANSWERS

SEARCH TIME: 00.00.01

L4 25 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 178.82 179.03

FILE 'CAPLUS' ENTERED AT 13:10:22 ON 23 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2008 VOL 149 ISS 13 FILE LAST UPDATED: 22 Sep 2008 (20080922/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s 14

L5 3 L4

=> d abs fbib hitstr 1-3

- L5 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
- AB A highly selective and efficient deprotection of the N-t-butoxy carbonyl (N-Boc) group on indoles, pyrroles, indazoles, and carbolines was achieved in high yields using a catalytic amount of NaOMe as a base in dry MeOH, at ambient temperature
- AN 2007:330985 CAPLUS
- DN 146:481964
- TI Simple and selective removal of the t-butyloxycarbonyl (Boc) protecting group on indoles, pyrroles, indazoles, and carbolines
- AU Ravinder, K.; Reddy, A. Vijender; Mahesh, K. Chinni; Narasimhulu, M.; Venkateswarlu, Y.
- CS Natural Products Laboratory, Organic Chemistry Division I, Indian Institute of Chemical Technology, Hyderabad, India
- SO Synthetic Communications (2007), 37(2), 281-287

23/09/2008 Page 3

CODEN: SYNCAV; ISSN: 0039-7911

PB Taylor & Francis, Inc.

DT Journal

LA English

OS CASREACT 146:481964

IT 935875-02-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(selective removal of t-butyloxycarbonyl protecting group on indoles,
pyrroles, indazoles, and carbolines using sodium methanolate in
methanol)

RN 935875-02-8 CAPLUS

CN 9H-Pyrido[3,4-b]indole-9-carboxylic acid, 3-[[[2-[4,5-dihydro-2-[[(trifluoromethyl)sulfonyl]amino]-1H-imidazol-5-yl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

IT 935875-08-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (selective removal of t-butyloxycarbonyl protecting group on indoles, pyrroles, indazoles, and carbolines using sodium methanolate in methanol)

RN 935875-08-4 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-[4,5-dihydro-2-[(trifluoromethyl)sulfonyl]amino]-1H-imidazol-5-yl]ethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} H & O \\ N & O \\ C - NH - CH_2 - CH_2 \\ \hline N & O \\ \end{array}$$

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN GI

$$\begin{array}{c|c} & \text{CO-NH-CH}_2\text{-CH}_2 \\ \hline & \text{NH} \\ & \text{NH} \end{array}$$

AB The isolation and synthesis of the racemic form of a novel $\beta\text{-carboline}$ guanidine alkaloid, tiruchanduramine (I), a potent $\alpha\text{-glucosidase}$ inhibitor from the Indian ascidian, Synoicum macroglossum has been achieved.

AN 2005:614681 CAPLUS

DN 143:169694

TI Isolation and synthesis of a novel β -carboline guanidine derivative tiruchanduramine from the Indian ascidian Synoicum macroglossum

AU Ravinder, K.; Reddy, A. Vijender; Krishnaiah, P.; Ramesh, P.; Ramakrishna, S.; Laatsch, H.; Venkateswarlu, Y.

Page 4

CS Natural Products Laboratory, Organic Chemistry Division-I, Indian Institute of Chemical Technology, Hyderabad, 500 007, India

SO Tetrahedron Letters (2005), 46(33), 5475-5478 CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier B.V.

DT Journal

LA English

IT 858343-35-8P, Tiruchanduramine RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation) (isolation and synthesis of a novel β -carboline guanidine derivative tiruchanduramine from the Indian ascidian Synoicum macroglossum)

RN 858343-35-8 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-amino-4,5-dihydro-1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)

Currently available stereo shown.

IT 861390-41-2, (±)-Tiruchanduramine RL: RCT (Reactant); RACT (Reactant or reagent) (isolation and synthesis of a novel β -carboline guanidine derivative tiruchanduramine from the Indian ascidian Synoicum macroglossum)

RN 861390-41-2 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-amino-4,5-dihydro-1H-imidazol-5-yl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

$$\begin{array}{c|c}
H & O \\
N & C \\
\hline
C - NH - CH_2 - CH_2
\end{array}$$

● HCl

IT 861257-04-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(isolation and synthesis of a novel $\beta\text{-carboline}$ guanidine derivative tiruchanduramine from the Indian ascidian Synoicum macroglossum)

RN 861257-04-7 CAPLUS

CN 1,3-Imidazolidinedicarboxylic acid, 2-[[(1,1-dimethylethoxy)carbonyl]imino]-4-[2-[(9H-pyrido[3,4-b]indol-3-ylcarbonyl)amino]ethyl]-,

1,3-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN GI

23/09/2008 Page 6

The invention relates to a process for the isolation of β -carboline AΒ guanidine alkaloid, tiruchenduramine I [R1-R3 = H, n = 2, X = NH] and its derivs., I [R1 = H, piperazine; R2, R3 = H; n = 2-6; X = NH, O], from theIndian ascidian Synoicum macroglossum. I are useful in the treatment of diabetic disorder by providing inhibition of α -glucosidase.

ΑN 2005:612288 CAPLUS

143:130287 DN

- Isolation of β -carboline derived guanidine alkaloid, tiruchenduramine ΤI and its derivatives from Indian ascidian Synoicum macroglossum and their use in the treatment of diabetic disorder
- ΤN Venkateswarlu, Yenamandra; Ravinder, Kodela; Yadav, Jhillu Singh; Sarathkumar, Yandrapu; Ramakrishna, Sistla; Diwan, Prakash Vamanarao; Rao, Janapala Venkateswara; Ramesh, Ratnam; Laatsch, Hartmut
- Council of Scientific and Industrial Research, India; Department of Ocean PADevelopment
- PCT Int. Appl., 21 pp. SO

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

```
APPLICATION NO.
    PATENT NO.
                       KIND DATE
                               _____
                                           _____
                       ____
                              20050714
    WO 2005063748
                        A1
                                          WO 2003-IN444
                                                                  20031231
PΙ
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           AU 2003-300701
     AU 2003300701
                         Α1
                               20050721
                                                                  20031231
                                           WO 2003-IN444 A 20031231
US 2004-814777 20040330
WO 2003-IN444 A 20031231
     US 20050222168
                         Α1
                               20051006
ΙT
     857840-45-0P 857840-46-1P 857840-47-2P
     857840-48-3P 857840-49-4P 857840-50-7P
     857840-52-9P 857840-54-1P 857840-55-2P
```

857840-56-3P 857840-57-4P 857840-59-6P

857840-61-0P 857840-63-2P 857840-64-3P

857840-65-4P 857840-66-5P 857840-67-6P

857840-68-7P 858343-35-8P, Tiruchenduramine

RL: IMF (Industrial manufacture); NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (isolation of tiruchenduramine and its derivs. from Indian ascidian Synoicum macroglossum and their use in the treatment of diabetic disorder)

857840-45-0 CAPLUS RN

9H-Pyrido[3,4-b]indole-3-carboxamide, N-[3-(2-amino-4,5-dihydro-1Himidazol-5-yl)propyl]- (CA INDEX NAME)

RN 857840-46-1 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-5-yl)butyl]- (CA INDEX NAME)

RN 857840-47-2 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[5-(2-amino-4,5-dihydro-1H-imidazol-5-yl)pentyl]- (CA INDEX NAME)

RN 857840-48-3 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[6-(2-amino-4,5-dihydro-1H-imidazol-5-yl)hexyl]- (CA INDEX NAME)

RN 857840-49-4 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-oxo-4-imidazolidinyl)ethyl]-(CA INDEX NAME)

$$\begin{array}{c|c} H & O & H \\ \hline N & O & H \\ \hline C - NH - CH_2 - CH_2 & H \\ N & H \end{array}$$

RN 857840-50-7 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[3-(2-oxo-4-imidazolidinyl)propyl]- (CA INDEX NAME)

RN 857840-52-9 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[4-(2-oxo-4-imidazolidinyl)butyl](CA INDEX NAME)

$$\begin{array}{c|c}
H & O \\
N & C - NH - (CH_2)_4
\end{array}$$

RN 857840-54-1 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[5-(2-oxo-4-imidazolidinyl)pentyl]- (CA INDEX NAME)

RN 857840-55-2 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[6-(2-oxo-4-imidazolidinyl)hexyl](CA INDEX NAME)

RN 857840-56-3 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-amino-4,5-dihydro-1H-imidazol-5-yl)ethyl]-6-(1-piperazinyl)- (CA INDEX NAME)

RN 857840-57-4 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[3-(2-amino-4,5-dihydro-1H-imidazol-5-yl)propyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c}
H & O \\
N & C \\
NH - (CH_2)_3 \\
N & NH_2
\end{array}$$

RN 857840-59-6 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-5-yl)butyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 857840-61-0 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[5-(2-amino-4,5-dihydro-1H-imidazol-5-yl)pentyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} H & O & H \\ \hline N & C - NH - (CH_2)_5 & NH_2 \end{array}$$

RN 857840-63-2 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[6-(2-amino-4,5-dihydro-1H-imidazol-5-yl)hexyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c}
 & H \\
 & N \\
 & C \\
 & N \\
 & C \\
 & N \\$$

RN 857840-64-3 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-oxo-4-imidazolidinyl)ethyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} H \\ N \\ \end{array} \begin{array}{c|c} O \\ C \\ \end{array} \begin{array}{c} H \\ C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} C \\ \end{array} \begin{array}{$$

RN 857840-65-4 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[3-(2-oxo-4-imidazolidinyl)propyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} H \\ N \\ \hline \end{array} \begin{array}{c} H \\ C \\ \hline \end{array} \begin{array}{c} N \\ \hline \end{array} \begin{array}{c} C \\ \hline \end{array} \begin{array}{c} H \\ C \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} N \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} N \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} N \\ \end{array} \begin{array}{$$

RN 857840-66-5 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[4-(2-oxo-4-imidazolidinyl)butyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} H \\ N \\ \hline \end{array} \begin{array}{c} N \\ \hline \end{array} \begin{array}{c} O \\ C \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} O$$

RN 857840-67-6 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[5-(2-oxo-4-imidazolidinyl)pentyl]- 6-(1-piperazinyl)- (CA INDEX NAME)

RN 857840-68-7 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[6-(2-oxo-4-imidazolidinyl)hexyl]-6-(1-piperazinyl)- (CA INDEX NAME)

$$\begin{array}{c|c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ C \\ \hline \end{array} \begin{array}{c} H \\ C \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \hline \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} O \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} N \\ \end{array} \begin{array}{c} H \\ N \\ \end{array} \begin{array}{c} N \\ \end{array} \begin{array}$$

RN 858343-35-8 CAPLUS

CN 9H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-(2-amino-4,5-dihydro-1H-imidazol-5-yl)ethyl]- (CA INDEX NAME)

Currently available stereo shown.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT